ClinicalTrials.Veeva

Menu
G

Global Research Management, Inc. | Glendale, CA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

AMDX-2011P
AGN-190584
AR-15512
Timolol Maleate
DE-117
Pilocarpine
AZR-MD-001
Pilocarpine HCl
Bimatoprost
BI 771716

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

13 of 48 total trials

A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56

This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.

Enrolling
Wet Age Related Macular Degeneration
wAMD
Drug: Aflibercept (2.0 mg)
Drug: EYP-1901

This study is a multicenter, double-masked, vehicle-controlled, randomized, parallel group study designed to evaluate the treatment of abnormal meibo...

Active, not recruiting
Dry Eye Disease
Other: Vehicle
Drug: AZR-MD-001

The primary purpose of the study is to determine if IVT injections of ANX007 every month reduce vision loss in participants with GA secondary to age-...

Enrolling
Geographic Atrophy
Drug: ANX007
Other: Sham Administration

The purpose of this study is to assess safety, tolerability, plasma pharmacokinetics and biologic activity of a single intravenous dose of AMDX-2011P...

Enrolling
Alzheimer Disease
Drug: AMDX-2011P

The purpose of this study is to assess safety, tolerability, plasma pharmacokinetics and biologic activity of a single intravenous dose of AMDX-2011P...

Enrolling
Cerebral Amyloid Angiopathy
Drug: AMDX-2011P

The purpose of this research study is to assess the ability of AMDX- 2011P to identify amyloid deposits in the retina of participants with Primary Op...

Enrolling
Primary Open Angle Glaucoma
Drug: AMDX-2011P

In this prospective, phase 2b, multicenter, randomized, double-masked, vehicle-controlled, parallel-arm study, approximately 880 subjects with modera...

Active, not recruiting
Dry Eye Disease
Drug: TL-925
Other: Placebo

This study is open to adults aged 55 years and older with geographic atrophy that was diagnosed by imaging of the retina. The purpose of this study i...

Enrolling
Geographic Atrophy
Drug: BI 1584862
Drug: Placebo-matching BI 1584862

This study is open to people 50 years or older with an eye condition called geographic atrophy. The purpose of this study is to compare a medicine ca...

Enrolling
Macular Degeneration, Age-related
Geographic Atrophy
Drug: Pegcetacoplan
Drug: Sham comparator to BI 771716
Locations recently updated

This is a multicenter, open-label, dose escalation (Cohort 1) to masked, randomized, parallel-groups (Cohort 2) and (Cohort 3) study to evaluate the...

Enrolling
Open-angle Glaucoma
Ocular Hypertension
Other: Sham Administration
Drug: AGN-193408 SR

The main purpose is to compare the ocular hypotensive efficacy and safety of two concentrations of T4090 (Kinezodianone R HCl 0.2% and 0.3%) ophthalm...

Active, not recruiting
Glaucoma
Ocular Hypertension
Drug: Rhopressa®
Drug: T4090 0.3%

Randomized contralateral eye study to evaluate the effect of one-time dosing of NV701 versus commercially available 1.25% pilocarpine solution on pup...

Active, not recruiting
Pupil Constriction
Drug: NV701
Drug: Pilocarpine 1.25% Eye drop

STUDY DESIGN:Structure:Multicenter, randomized, double-masked, vehicle-controlled, parallel-group study.Duration of Treatment:4 weeks of study treatm...

Enrolling
Pinguecula
Drug: CBT-004

Trial sponsors

Allergan logo
S
Aerie Pharmaceuticals logo
A
AbbVie logo
Boehringer Ingelheim logo
Thea Pharma logo
Alcon logo
A
A

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems